TWI315986B - Compositions and methods for treating or preventing pneumococcal infection - Google Patents

Compositions and methods for treating or preventing pneumococcal infection

Info

Publication number
TWI315986B
TWI315986B TW092131025A TW92131025A TWI315986B TW I315986 B TWI315986 B TW I315986B TW 092131025 A TW092131025 A TW 092131025A TW 92131025 A TW92131025 A TW 92131025A TW I315986 B TWI315986 B TW I315986B
Authority
TW
Taiwan
Prior art keywords
compositions
treating
methods
pneumococcal infection
preventing pneumococcal
Prior art date
Application number
TW092131025A
Other languages
English (en)
Chinese (zh)
Other versions
TW200418502A (en
Inventor
C Chen Michael
Chiou Chuang-Jiun
Li Zhongming
Chen Dong-Sheng
Original Assignee
Synergy America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy America Inc filed Critical Synergy America Inc
Publication of TW200418502A publication Critical patent/TW200418502A/zh
Application granted granted Critical
Publication of TWI315986B publication Critical patent/TWI315986B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW092131025A 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection TWI315986B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07

Publications (2)

Publication Number Publication Date
TW200418502A TW200418502A (en) 2004-10-01
TWI315986B true TWI315986B (en) 2009-10-21

Family

ID=32312819

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092131025A TWI315986B (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Country Status (10)

Country Link
US (2) US7217791B2 (enExample)
EP (1) EP1558280B1 (enExample)
JP (3) JP2006506989A (enExample)
KR (1) KR20050086427A (enExample)
CN (1) CN100443116C (enExample)
AU (1) AU2003291365B2 (enExample)
CA (1) CA2504938C (enExample)
ES (1) ES2451620T3 (enExample)
TW (1) TWI315986B (enExample)
WO (1) WO2004043376A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8226959B2 (en) 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
MX383544B (es) * 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
CA2851270C (en) * 2011-10-05 2023-03-14 The Rockefeller University Dimeric bacteriophage lysins
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
US12616744B2 (en) 2014-01-21 2026-05-05 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
ES2993430T3 (en) 2014-11-21 2024-12-30 Univ Oklahoma Pneumolysin mutants and methods of use thereof
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
HUE068482T2 (hu) 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3237842B2 (ja) 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
EP0687688A1 (en) * 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO2000006737A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1238086B1 (en) * 1999-12-17 2006-03-08 Wyeth Holdings Corporation Vaccine for enhancing immune responses to herpes simplex virus

Also Published As

Publication number Publication date
WO2004043376A2 (en) 2004-05-27
AU2003291365B2 (en) 2009-06-11
JP2006506989A (ja) 2006-03-02
US7585669B2 (en) 2009-09-08
ES2451620T3 (es) 2014-03-28
KR20050086427A (ko) 2005-08-30
HK1074005A1 (en) 2005-10-28
US20040213803A1 (en) 2004-10-28
JP2010057501A (ja) 2010-03-18
US7217791B2 (en) 2007-05-15
CA2504938A1 (en) 2004-05-27
CA2504938C (en) 2011-10-11
CN1711105A (zh) 2005-12-21
EP1558280A2 (en) 2005-08-03
TW200418502A (en) 2004-10-01
US20080199952A1 (en) 2008-08-21
CN100443116C (zh) 2008-12-17
EP1558280A4 (en) 2007-08-29
AU2003291365A1 (en) 2004-06-03
WO2004043376A3 (en) 2004-10-14
JP2012139221A (ja) 2012-07-26
EP1558280B1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
EP1558280A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOCOCCAL INFECTION
AU2002254158A1 (en) Medical devices, compositions and methods for treating vulnerable plaque
GB0110288D0 (en) Composition and treatment method
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
AU2002367023A8 (en) Compositions and methods for treating heart failure
IL160010A0 (en) Methods and compositions for treating fungal infections
SG118236A1 (en) Compositions and methods for treating coronavirus infection and SARS
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
AU2003297573A8 (en) Compositions and methods for treating transplants
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
AU2002365057A8 (en) Compositions and methods for treating heart failure
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
AU2003296963A8 (en) Methods and compositions for treating and preventing ear infections
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
ZA200602738B (en) Methods and compositions for treating herpes infections
AU5735701A (en) Seed treatment composition
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
IL175579A0 (en) Epithelium treatment methods and devices for treating the epithelium
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003275069A8 (en) Compositions and methods for preventing infection
AU2003303948A8 (en) Compositions and methods for preventing infection
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2003275433A8 (en) Compositions and methods for treating pain
AU2003254129A8 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees